Wealth Enhancement Advisory Services LLC Buys New Position in ImmunityBio, Inc. $IBRX

Wealth Enhancement Advisory Services LLC purchased a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 15,933 shares of the company’s stock, valued at approximately $43,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Thrive Wealth Management LLC boosted its holdings in shares of ImmunityBio by 49.3% during the 2nd quarter. Thrive Wealth Management LLC now owns 15,041 shares of the company’s stock worth $40,000 after buying an additional 4,964 shares in the last quarter. XTX Topco Ltd raised its position in shares of ImmunityBio by 5.4% during the first quarter. XTX Topco Ltd now owns 111,647 shares of the company’s stock worth $336,000 after purchasing an additional 5,764 shares during the period. Crestwood Advisors Group LLC raised its position in shares of ImmunityBio by 37.0% during the first quarter. Crestwood Advisors Group LLC now owns 22,200 shares of the company’s stock worth $67,000 after purchasing an additional 6,000 shares during the period. Rathbones Group PLC raised its position in shares of ImmunityBio by 8.1% during the first quarter. Rathbones Group PLC now owns 96,620 shares of the company’s stock worth $291,000 after purchasing an additional 7,200 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in shares of ImmunityBio by 4.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 205,092 shares of the company’s stock worth $635,000 after purchasing an additional 8,892 shares during the period. 8.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research report on Wednesday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Saturday, September 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of ImmunityBio in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.75.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $2.36 on Monday. The company has a market capitalization of $2.32 billion, a PE ratio of -4.92 and a beta of 0.27. The business has a fifty day moving average price of $2.49 and a two-hundred day moving average price of $2.63. ImmunityBio, Inc. has a 1 year low of $1.83 and a 1 year high of $7.48.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million. Sell-side analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.